Search

Displaying results 2061 - 2070 of 10000 in total
  1. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim.

  2. Drug

    Corticorelin

    go.drugbank.com/drugs/DB05394
    Investigational

    It is a type of neurohormone, also called hCRF. … Corticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory.

  3. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. … Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers.

    Categories: Interferon Type I, Cytochrome P-450 CYP1A2 Inhibitors
  4. Drug

    Succinobucol

    go.drugbank.com/drugs/DB05399
    Investigational

    AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary

  5. Drug

    Pipendoxifene

    go.drugbank.com/drugs/DB05414
    Investigational

    Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment … ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  6. Drug

    Cardarine

    go.drugbank.com/drugs/DB05416
    Investigational

    Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia.

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high. … ORG-34517 is currently under investigation by Organon for the treatment of depression.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  8. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. … It is developed by MedImmune for the treatment of Allergic Rhinitis.

    Synonyms: IMMUNOGLOBULIN G4, ANTI-(HUMAN EOTAXIN 1) (HUMAN MONOCLONAL CAT-213 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CAT-213 .KAPPA.-CHAIN, DIMER
  9. Drug

    ABT-510

    go.drugbank.com/drugs/DB05434
    Investigational

    ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. … It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.

  10. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal